Hypertriglyceridemia and atherosclerosis risk

Czech version

Authors: Rudolf Poledne; Jan Kovář
Authors‘ workplace: Laboratoř pro výzkum aterosklerózy, Centrum experimentální medicíny IKEM, Praha
Published in: Vnitř Lék 2019; 65(12): 783-787
Category:

Overview

The history of studying hypertriglyceridemia as a risk factor for atherosclerosis has been going on for a half a century. The significance of this parameter as measured in fasting state is not entirely clear, since the statistical significance between triglyceride concentration and cardiovascular risk is lost after adjustment to HDL-cholesterol concentration. Remnant particles of chylomicrons and very low density lipoproteins measured postprandially appear to be responsible for the risk associated with hypertriglyceridemia. As the concentration of non-fasting triglycerides increases, the risk of myocardial infarction increases gradually up to five times.

Keywords:

atherosclerosis risk – insulin resistance – liver – triglyceride

Sources

Gofman J, Strisower B, deLalla O et al. Index of coronary artery atherogenesis. Mod Med 1953; 21: 119–140.
Zilversmit DB. A proposal linking atherogenesis to the interaction of endothelial lipoprotein lipase with triglyceride-rich lipoproteins. Circ Res 1973; 33(6): 633–638. Dostupné z DOI: <http://dx.doi.org/10.1161/01.res.33.6.633>.
Zilversmit DB. Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins. Clin Chem 1995; 41(1): 153–158.
Criqui MH, Heiss G, Cohn R et al. Plasma triglyceride level and mortality from coronary heart disease. NEJM 1993; 328(17): 1220–1225. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM199304293281702>.
Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991; 11(1): 2–14. Dostupné z DOI: <http://dx.doi.org/10.1161/01.atv.11.1.2>.
NIH Consensus conference. Triglyceride, high-density lipoprotein, and coronary heart disease. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease. JAMA 1993; 269(4): 505–510.
Young SG, Zechner R. Biochemistry and pathophysiology of intravascular and intracellular lipolysis. Genes Dev 2013; 27(5): 459–484. Dostupné z DOI: <http://dx.doi.org/10.1101/gad.209296.112>.
Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3(2): 213–219
Adiels M, Taskinen MR, Packard C et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006; 49(4): 755–765. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–005–0125-z>.
Havel RJ. George Lyman Duff memorial lecture. Role of the liver in atherosclerosis. Arteriosclerosis 1985; 5(6): 569–580. Dostupné z DOI: <http://dx.doi.org/10.1161/01.atv.5.6.569>.
Langsted A, Freiberg JJ, Tybjærg-Hansen A et al. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med 2011; 270(1): 65–75. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2796.2010.02333.x>.
Kolovou GD, Mikhailidis DP, Kovar J et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: An expert panel statement. Curr Vasc Pharmacol 2011; 9(3): 258–270. Dostupné z DOI: <http://dx.doi.org/10.2174/157016111795495549>.
Hegele RA, Ginsberg HN, Chapman MJ et al. The polygenic nature of hypertriglyceridaemia: Implications for definition, diagnosis and management. Lancet Diabetes Endocrinol 2013; 2(8): 655–666. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(13)70191–8>.